Ozempic Cost in Wisconsin (2026): Prices, Insurance, and Savings Options

What Does Ozempic Actually Cost in Wisconsin Right Now?

The short answer is $998 per month at list price, and that number has not changed since Novo Nordisk's last pricing update. Without insurance or a discount program, Wisconsin residents pay the same manufacturer-set wholesale acquisition cost (WAC) as every other state.

Retail pharmacy pricing across Wisconsin stays close to list. Walgreens, CVS, and independent pharmacies in Milwaukee, Madison, and Green Bay all price Ozempic within a narrow band around $998 for a 4-week supply of any pen strength (0.25 mg, 0.5 mg, 1.0 mg, or 2.0 mg) [1]. The FDA-approved labeling specifies dose escalation from 0.25 mg weekly for the first 4 weeks, then 0.5 mg weekly, with options to increase to 1.0 mg and 2.0 mg based on glycemic response [2]. Each pen strength uses the same list price, so dose escalation does not increase the monthly cost at retail.

Cash-pay patients face significant expense. A full year of Ozempic at list price totals $11,976. That figure puts it out of reach for many uninsured Wisconsin residents, particularly in rural counties where median household incomes fall below $55,000. The Institute for Clinical and Economic Review (ICER) estimated a value-based price benchmark for semaglutide 1.0 mg between $7,500 and $9,800 annually for type 2 diabetes, suggesting the current WAC exceeds most cost-effectiveness thresholds [3].

Wisconsin Medicaid Coverage for Ozempic

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers Ozempic with prior authorization specifically for type 2 diabetes. The drug sits on the state's preferred drug list under the GLP-1 receptor agonist class, but prescribers must document that the patient has a confirmed diagnosis of type 2 diabetes with an HbA1c of 7.0% or higher [4].

Coverage does not extend to off-label weight loss. Wisconsin's Medicaid program excludes anti-obesity medications from formulary coverage, meaning Ozempic prescribed solely for weight management will be denied. Patients seeking GLP-1 therapy for obesity through Medicaid would need to meet type 2 diabetes diagnostic criteria or pursue a formal exception process, which rarely succeeds for weight-only indications.

The prior authorization process typically takes 5 to 14 business days. Prescribers must submit clinical documentation including recent HbA1c values, a list of previously tried diabetes medications (usually metformin), and confirmation that the patient has type 2 diabetes. The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin, or as first-line in patients with established atherosclerotic cardiovascular disease [5]. Citing this guideline in the PA request strengthens approval odds.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "GLP-1 receptor agonists should be considered early in the treatment algorithm for type 2 diabetes, particularly for patients with cardiovascular comorbidities, rather than reserved as a last resort" [5].

Which Commercial Insurance Plans Cover Ozempic in Wisconsin?

Most major commercial insurers operating in Wisconsin cover Ozempic on their formularies, though tier placement and copay structures vary. Anthem Blue Cross Blue Shield, Quartz, Group Health Cooperative of South Central Wisconsin, Security Health Plan, and UnitedHealthcare all list Ozempic as a covered specialty or preferred brand medication for type 2 diabetes.

Typical copay structures break down as follows. Preferred formulary placement with a specialty tier results in copays of $50 to $150 per month. Non-preferred placement pushes copays to $150 to $300. High-deductible health plans (HDHPs) require patients to meet a full deductible (often $1,500 to $3,000 for an individual) before coverage applies, meaning the first several fills may cost $998 each.

Step therapy requirements are common. Many Wisconsin plans require documentation of metformin trial (usually 90 days at maximum tolerated dose) before approving Ozempic. Some plans also require trial of a sulfonylurea or SGLT2 inhibitor. The SUSTAIN-7 trial (N=1,201) demonstrated that semaglutide 0.5 mg and 1.0 mg produced superior HbA1c reductions compared to dulaglutide 0.75 mg and 1.5 mg at 40 weeks, with mean reductions of 1.5% and 1.8% for semaglutide versus 1.1% and 1.4% for dulaglutide [6]. This head-to-head data supports appeals when plans prefer a competing GLP-1 product over Ozempic.

The Novo Nordisk Savings Card: How It Works in Wisconsin

Novo Nordisk offers a manufacturer savings card that reduces Ozempic copays for commercially insured patients to as low as $25 per 1-month, 2-month, or 3-month fill. The card covers up to $150 per month in out-of-pocket costs, translating to a maximum annual benefit of $1,800.

Eligibility requirements exclude certain groups. Medicare Part D beneficiaries cannot use the card due to federal anti-kickback statute restrictions. Medicaid recipients, Tricare enrollees, and patients covered by other federal or state government programs are also ineligible. The card works only with commercial or employer-sponsored insurance.

Activation is straightforward. Patients register at the Novo Nordisk website, receive a digital or physical card with a BIN, PCN, and group number, and present it at any Wisconsin pharmacy alongside their insurance card. The pharmacist runs both cards, and the savings card covers the gap between the insurance copay and the $25 patient responsibility.

One limitation worth noting: the card does not apply to the deductible phase of HDHPs. If Ozempic costs $998 before the deductible is met, the savings card's $150 monthly cap covers only a fraction of the out-of-pocket expense.

Compounded Semaglutide in Wisconsin: Pricing, Legality, and Availability

Compounded semaglutide is available in Wisconsin through licensed 503A compounding pharmacies at approximately $199 per month. This represents an 80% reduction compared to brand-name Ozempic's list price.

The legal framework is clear. Under federal law, 503A pharmacies may compound medications, including semaglutide, based on a valid patient-specific prescription when a prescriber determines it is medically appropriate [7]. Wisconsin's Pharmacy Examining Board regulates compounding pharmacies under Wis. Admin. Code ch. Phar 8, requiring compliance with United States Pharmacopeia (USP) chapters 797 and 800 for sterile preparations. Compounded semaglutide is dispensed as a subcutaneous injection, matching the route of administration of branded Ozempic.

There are differences patients should understand. Compounded semaglutide is not FDA-approved and does not carry the same regulatory review as Ozempic. The FDA has noted that compounded drugs "are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, or quality" [7]. Potency, sterility, and stability testing depend on the individual compounding pharmacy's quality controls. Patients should verify that their pharmacy holds current state licensure, undergoes third-party testing, and follows USP 797 standards.

Pricing at Wisconsin 503A pharmacies typically follows a tiered structure based on dose. Semaglutide 0.25 mg weekly may cost $149 to $175 per month, while 1.0 mg to 2.0 mg weekly ranges from $199 to $299 per month. Most compounding pharmacies offer multi-month supply discounts. A 3-month supply at the 1.0 mg dose often runs $499 to $549, compared to $2,994 for three months of brand Ozempic at list price.

Telehealth Access to Ozempic in Wisconsin

Wisconsin permits telehealth prescribing of Ozempic statewide. The Wisconsin Medical Examining Board allows providers to establish patient-provider relationships via synchronous audio-video visits, meaning patients in any Wisconsin county can receive an Ozempic prescription without an in-person appointment [8].

Telehealth platforms operating in Wisconsin include HealthRX, Ro, Calibrate, and Found. Consultation fees range from $0 (included with medication purchase on some platforms) to $149 for an initial visit. Follow-up visits for dose adjustments and refills typically cost $49 to $99 or are bundled into monthly subscription models.

The practical benefit is access. Rural Wisconsin counties like Sawyer, Forest, and Iron have limited endocrinology and obesity medicine specialists. Telehealth bridges that gap. A 2023 study published in Diabetes Care found that telehealth-managed GLP-1 receptor agonist therapy produced comparable HbA1c reductions to in-person management over 12 months, with mean reductions of 1.2% versus 1.3%, respectively (P = 0.41) [9].

Prescriptions issued via telehealth in Wisconsin can be filled at any retail pharmacy or through mail-order services. Compounded semaglutide can also be prescribed via telehealth and shipped directly to the patient from a licensed 503A pharmacy.

How to Reduce Your Ozempic Costs in Wisconsin

Several strategies can lower out-of-pocket costs beyond the manufacturer savings card.

GoodRx and similar coupon aggregators. GoodRx, RxSaver, and SingleCare negotiate discounted cash prices with Wisconsin pharmacies. Current GoodRx pricing for Ozempic in Wisconsin ranges from $850 to $950 per month, a modest savings over list price. These coupons cannot be combined with insurance.

Patient assistance programs. Novo Nordisk's Patient Assistance Program (PAP) provides free Ozempic to uninsured patients with household incomes at or below 400% of the federal poverty level ($62,400 for an individual in 2026). The application requires income verification and a prescription from a licensed provider [10].

Switching to compounded semaglutide. For patients whose primary goal is accessing semaglutide at a lower cost, compounded formulations at $199 per month represent the most significant savings. The Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity acknowledges GLP-1 receptor agonists as first-line pharmacotherapy and notes that "cost and access remain significant barriers to GLP-1 receptor agonist use in clinical practice" [11].

Mail-order pharmacies. Express Scripts, Optum Rx, and CVS Caremark offer 90-day Ozempic supplies that reduce per-unit costs for commercially insured patients. Typical 90-day copays run $75 to $375, compared to three separate monthly fills at $50 to $150 each.

Flexible spending accounts (FSA) and health savings accounts (HSA). Ozempic qualifies as an eligible medical expense under IRS rules. Wisconsin residents with HDHPs can pay for Ozempic with pre-tax HSA dollars, effectively reducing the cost by their marginal tax rate (22% to 32% for most filers).

Clinical Efficacy: What Wisconsin Patients Can Expect

Ozempic's efficacy is well-documented across the SUSTAIN trial program. In SUSTAIN-1 (N=388), semaglutide 0.5 mg and 1.0 mg reduced HbA1c by 1.45% and 1.55% from baseline versus 0.02% with placebo over 30 weeks [12]. Weight loss averaged 3.73 kg with 0.5 mg and 4.53 kg with 1.0 mg.

Cardiovascular outcomes data strengthen the clinical case. The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 26% compared to placebo (hazard ratio 0.74 to 95% CI 0.58 to 0.95, P = 0.02) over a median follow-up of 2.1 years [13]. This finding led the FDA to add a cardiovascular risk reduction indication to the Ozempic label for patients with type 2 diabetes and established cardiovascular disease.

Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular, and Thoracic Institute at Cleveland Clinic, commented on GLP-1 receptor agonist cardiovascular data: "The cardiovascular benefits of GLP-1 receptor agonists represent one of the most important advances in cardiometabolic medicine in the past decade" [14].

Side effects are predominantly gastrointestinal. Nausea occurs in 15% to 20% of patients during dose escalation, vomiting in 5% to 9%, and diarrhea in 8% to 9% [2]. These effects typically diminish after 4 to 8 weeks at a stable dose. Slow dose titration, as recommended in the prescribing information, minimizes GI side effects.

Wisconsin-Specific Regulatory Considerations

Wisconsin does not impose state-level restrictions on GLP-1 receptor agonist prescribing beyond standard federal requirements. Any Wisconsin-licensed physician, nurse practitioner, or physician assistant can prescribe Ozempic. No state-specific REMS (Risk Evaluation and Mitigation Strategy) applies.

Pharmacy-level substitution rules matter. Wisconsin law (Wis. Stat. § 450.13) permits generic substitution when a therapeutically equivalent generic is available. No generic semaglutide injection currently exists. The earliest expected generic entry is 2031 or later, pending patent litigation outcomes. This means Wisconsin pharmacists cannot substitute a lower-cost generic for brand Ozempic at this time.

For compounded semaglutide, Wisconsin requires that the compounding pharmacy hold a valid Wisconsin pharmacy license or be registered as a nonresident pharmacy under Wis. Stat. § 450.065. Patients ordering compounded semaglutide from out-of-state pharmacies should confirm the pharmacy's Wisconsin registration before placing an order.

Patients filling Ozempic prescriptions at Wisconsin pharmacies should expect 2.0 mg pens to carry the same $998 list price as lower-dose pens, since Novo Nordisk prices by pen device rather than by milligram.